{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:01:25Z","timestamp":1785214885802,"version":"3.55.0"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1055\/a-2697-1880","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:32:30Z","timestamp":1785191550000},"page":"802-812","source":"Crossref","is-referenced-by-count":0,"title":["Gastroenterologische Nebenwirkungen der Immun-Checkpunkt-Therapie"],"prefix":"10.1055","volume":"151","author":[{"given":"Alexandra Emilia","family":"Schlaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Bengsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis","volume":"109","author":"DL Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"BJ Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","article-title":"Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8 + T Cell Exhaustion","volume":"45","author":"B Bengsch","year":"2016","journal-title":"Immunity"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.13239","article-title":"Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions","volume":"318","author":"M Dougan","year":"2023","journal-title":"Immunol Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis","volume":"161","author":"SC Sasson","year":"2021","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41590-024-02027-0","article-title":"Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells","volume":"26","author":"Z Zhang","year":"2025","journal-title":"Nat Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.adh8342","article-title":"Microbiota-dependent activation of CD4 T cells induces CTLA-4 blockade-associated colitis via Fc\u03b3 receptors","volume":"383","author":"BC Lo","year":"2024","journal-title":"Science"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1186\/s12967-022-03755-3","article-title":"Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity","volume":"20","author":"Z Zhang","year":"2022","journal-title":"J Transl Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials","volume":"42","author":"RJ Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/hep.32215","article-title":"Effect of corticosteroid dosing on outcomes in high\u2010grade immune checkpoint inhibitor hepatitis","volume":"75","author":"M Li","year":"2022","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review","volume":"160","author":"M Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"J Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/apt.15263","article-title":"Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor\u2010induced colitis","volume":"49","author":"AP Wright","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"MS Hughes","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/apt.15998","article-title":"Systematic review with meta\u2010analysis: effectiveness of anti\u2010inflammatory therapy in immune checkpoint inhibitor\u2010induced enterocolitis","volume":"52","author":"H Ibraheim","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ccell.2025.01.004","article-title":"Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity","volume":"43","author":"LM Braun","year":"2025","journal-title":"Cancer Cell"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"E De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","article-title":"Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids","volume":"66","author":"M Ziemer","year":"2017","journal-title":"J Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2017.05.018","article-title":"Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins","volume":"81","author":"I Sp\u00e4nkuch","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.cgh.2023.12.008","article-title":"Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data","volume":"22","author":"L Meunier","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer","volume":"6","author":"C Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"X Zhou","year":"2020","journal-title":"BMC Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2697-1880.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:46:31Z","timestamp":1785213991000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2697-1880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2697-1880","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}